Nice to see some activity here. I just got this news release from Exten.
SAN DIEGO--(BUSINESS WIRE)--Aug. 4, 1997--
Considine To Direct the Scientific and Clinical Trial Programs
To Support Commercial Development of Tomorrow's Liver Support
Technology
Jerry Newmin, president of Exten Industries Inc., Monday
announced that Dr. James M. Considine had been appointed president
of Exten's subsidiary, Xenogenics Corp.
"Dr. Considine had been involved with the company's Sybiol
synthetic bio-liver support technology while serving as a consultant
to Exten's board of directors since 1996, and we are pleased to have
Dr. Considine take on the new executive position," Newmin stated.
Prior to joining Xenogenics, Considine had served as regional
vice president and medical director of Private Healthcare Systems
Inc. in Irvine, Calif. From 1989 to 1993, he held the vice
president and medical director positions with Pacificare Health
Systems and Pacific Review Services.
His medical management career also includes vice
presidencies/medical directorships at Travelers Health Network and
Maxicare Health Plan as well as U.S. Public Health Service
experience.
In announcing the appointment, Newmin, chief executive officer,
chairman and president of the parent corporation, stated: "With his
background in medicine, management and therapeutics, Dr. Considine
is well-positioned to ensure that the scientific development and
clinical trials for the artificial-liver technology are executed in
an efficient, focused manner, to get this much-needed technology to
the worldwide market of liver disease, liver trauma and
liver-transplant patients as soon as possible. We are committed to
perfecting the technology and commencing research at Yale University
within the year."
Considine's medical degree is from Loyola University, and he
received his MBA from the University of California at Los Angeles.
Considine stated that he is looking forward to working with
Xenogenics' scientific advisory board.
The board -- chaired by Dr. John Brems, F.A.C.S. Division of Organ
Transplantation and co-director Center for Liver Diseases at Scripps
Clinic in La Jolla, Calif., and including Dr. Amy Firedman, Chief
Liver Transplantation Services, Division of Organ Transplantation at
Yale University, and Dr. Kurt Gehlsen, vice president and chief
technical officer of Maxim Pharmaceuticals -- will work with other
national liver transplantation experts to further the goals of proving
to the Food and Drug Administration's satisfaction the Sybiol
synthetic bio-liver support technology's efficacy in extending the
function and regeneration of the human liver.
Xenogenics is a private corporation, a wholly owned subsidiary
of Exten Industries Inc., which is a publicly traded company.
Exten's common shares are listed on the Nasdaq Over-the-Counter
Bulletin Board (symbol EXTI).
-0-
Considine is married, has two children and has lived in Irvine
since 1988. He is active in the Sierra Club and enjoys outdoor
activities. |
